about
Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placeboCancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesOral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancerDifferential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.Long-term effects of inhaled budesonide on screening-detected lung nodules.Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotypeThe effect of metformin on apoptosis in a breast cancer presurgical trial.Circulating and tissue biomarkers in early-stage non-small cell lung cancerThe science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it.Breast cancer prevention by antihormones and other drugs: where do we stand?Acceptability of chemoprevention trials in high-risk subjects.Metformin: risk-benefit profile with a focus on cancer.Alternate dosing schedules for cancer chemopreventive agents.The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT studyDoes tamoxifen prophylaxis for breast cancer provide long-term prevention?Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trialThe risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysisEstimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breastPrognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breastDuctal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution seriesPrognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer
P50
Q21261269-645AE165-030A-4403-81BD-0CB8BCF6F5CFQ28080472-919525D0-6E9B-4D2A-9698-D5D0BCAD4371Q33739214-0879A605-EDC0-4A1D-BAB3-05B9B52AFA51Q33739494-EFF896C4-60C3-49D5-932E-C1ADEC25CF5AQ34334262-7644B7D6-20E9-47B7-8A89-1C9D392160A9Q35511821-73004115-301E-4D94-8870-2367058110FCQ35611834-AEA5BF8F-4BC6-4D0D-958C-510A2FFFF0D4Q35665099-07577E67-ED46-4E4D-8B1D-04DA1D0C6FA0Q36889682-8239B1E4-D843-4D02-A220-D3FE1878E3C5Q37352586-24B9A23A-10E9-44D2-98BC-F3C018D4B371Q37629653-331EB524-12AA-4891-91C2-18D541C9B28CQ37947907-C73B5044-0338-4F54-B6D9-7D99CE7C3EBAQ38126602-90E223B8-A7CC-45F7-B144-17AB2E1672B7Q38153183-6A487395-6118-4D87-9A96-62AFBDA50D5EQ38584636-3BE648D4-2E50-4E58-AC49-85A8F4277C3CQ38771358-D8BB1179-A8A8-49D0-9FBF-E7C6C6ACC875Q38828948-972EDE3D-A5B9-480E-8143-0441E960BEF8Q38841509-AD82145F-C734-4AD1-BC6B-CF038C8273D1Q38947085-81BFCE70-45E2-48FB-B8C0-DA9D52265072Q39163477-22E7A42E-D4A4-4C6A-BB15-85B25FE3AD2CQ40665794-EB6D96C3-BCE1-4A8C-9714-01CE5FF61496Q40879541-E78ECF9F-4345-416D-BD57-A642ED099071Q43120669-A8A5DCB9-F239-4D27-83B8-7DDC61C998E9Q43121565-2517AEE0-5B8D-4061-B1B9-F51BA4116010Q43254570-CE5F54B3-08C2-454C-9D0B-AD4F9FE4C911Q46098809-119A1D31-7636-4B60-BABE-2F0A638E9BBFQ50592584-75A08069-E17D-468B-8B50-1C6FB251FC6BQ50863725-876F90C9-789B-42D9-8BEA-0D6D131877A5Q51357213-0CEEAFDD-BA7E-4A74-9E2D-E79835D38013Q52924405-DF1E86CB-5C1C-4130-828C-03E382EFB0ACQ53329790-5DD81276-D9D8-4276-A731-9C7897F23C26Q55070975-CB200E22-CA34-40BD-A7B1-F8F3A5797FDDQ56779153-37005293-2A4F-4194-8C3A-90B19BD8227DQ80984932-F0B48099-6A19-4DC3-82D8-12D1685328F2Q84390454-BA656161-EAA9-4A38-862F-9F0B0960014DQ91645090-2C9E64A5-F36E-40A8-90AF-33781B8E109AQ91989178-88F666BB-FA24-410B-B743-8AC6E5D766DFQ92564737-13E9C037-020E-4337-9C5C-2544F5D04EFFQ92761710-5B9C6EA8-CFBA-45A4-9782-3D4B0A591852Q92987129-A2B77F3F-9099-43A6-93D1-D7C9B8FAE3DE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matteo Lazzeroni
@ast
Matteo Lazzeroni
@en
Matteo Lazzeroni
@es
Matteo Lazzeroni
@nl
Matteo Lazzeroni
@sl
type
label
Matteo Lazzeroni
@ast
Matteo Lazzeroni
@en
Matteo Lazzeroni
@es
Matteo Lazzeroni
@nl
Matteo Lazzeroni
@sl
prefLabel
Matteo Lazzeroni
@ast
Matteo Lazzeroni
@en
Matteo Lazzeroni
@es
Matteo Lazzeroni
@nl
Matteo Lazzeroni
@sl
P106
P1153
16244973400
P21
P31
P496
0000-0002-2162-4002